Pharmaceuticals & Biotechnology Editor | 05/19/2010
The Health Protection Agency's Process & Analytical Development Group (PADG) has completed studies for an international Biopharm company to support validation of a bacterial toxin manufacturing process. The product is a therapeutic form of a botulinum toxin and was originally developed and manufactured in HPA’s GMP manufacturing facilities at Porton Down. The validation studies were on the downstream processing stages of the process using scaled down models.
Download PDF Attachment
RECOMMENDED
The Trust Equation: Why Transparency Defines the Future Winners in Contract Manufacturing
2025-12-17
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More